This Article Full Text Full Text (PDF) All Versions of this Article: 23/10/1857    most recent 01.ATV.0000094433.98445.7Fv1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schlitt, A. Articles by Jiang, X.-C. Search for Related Content PubMed PubMed Citation Articles by Schlitt, A. Articles by Jiang, X.-C. Related Collections Risk Factors Other arteriosclerosis

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1857.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

High Plasma Phospholipid Transfer Protein Levels as a Risk Factor for Coronary Artery Disease

Axel Schlitt; Christoph Bickel; Prathima Thumma; Stefan Blankenberg; Hans J. Rupprecht; Juergen Meyer; Xian-Cheng Jiang

From the Department of Anatomy and Cell Biology (P.T., X.-C.J.), State University of New York, Downstate Medical Center, Brooklyn, NY, and Department of Medicine II (C.B., S.B., H.J.R., A.S., J.M.), Johannes Gutenberg-University, Mainz, Germany.

Correspondence to Dr Xian-Cheng Jiang, Department of Anatomy and Cell Biology, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Box 5, Brooklyn, NY 11203. E-mail xjiang{at}downstate.edu

Objective— Plasma phospholipid transfer protein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Animal studies have shown that it is closely related to the development of atherosclerosis. PLTP-deficient mice have demonstrated increased antioxidation potential as well as a decrease in apolipoprotein B secretion and atherosclerotic lesions. In humans, high PLTP is associated with type II diabetes and obesity.

Methods and Results— To assess the relationship between PLTP activity and coronary artery disease (CAD), a novel, high-throughput method to measure plasma PLTP activity was used, relating it to CAD in 1102 cases and 444 controls. This demonstrated that PLTP activity in patients with CAD was significantly higher than in controls (25.5 versus 22.4 pmol/µL per h; P<0.0001). Using multivariate logistic regression analysis, PLTP activity was found to have independent predictive value for CAD. Patients within the highest quintile of PLTP activity revealed a 1.9-fold increase in risk for CAD compared with patients within the lowest quintile.

Conclusions— These findings indicate that PLTP activity is positively and independently related to CAD and suggest that (1) prospective studies to evaluate this relationship are warranted and (2) PLTP should be considered a therapeutic target.

Key Words: phospholipid transfer protein • risk factors • coronary artery disease

This article has been cited by other articles:

				A. Schlitt, S. Blankenberg, C. Bickel, K. J. Lackner, G. H. Heine, M. Buerke, K. Werdan, L. Maegdefessel, U. Raaz, H. J. Rupprecht, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study J. Lipid Res., April 1, 2009; 50(4): 723 - 729. [Abstract] [Full Text] [PDF]

				H. Samyn, M. Moerland, T. van Gent, R. van Haperen, J. Metso, F. Grosveld, M. Jauhiainen, A. van Tol, and R. de Crom Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study J. Lipid Res., December 1, 2008; 49(12): 2504 - 2512. [Abstract] [Full Text] [PDF]

				L. Shelly, L. Royer, T. Sand, H. Jensen, and Y. Luo Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice J. Lipid Res., April 1, 2008; 49(4): 773 - 781. [Abstract] [Full Text] [PDF]

				R. P F Dullaart, A. K Groen, G. M Dallinga-Thie, R. de Vries, W. J Sluiter, and A. van Tol Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol Eur. J. Endocrinol., January 1, 2008; 158(1): 53 - 60. [Abstract] [Full Text] [PDF]

				D. T. Valenta, J. J. Bulgrien, D. J. Bonnet, and L. K. Curtiss Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency J. Lipid Res., January 1, 2008; 49(1): 24 - 32. [Abstract] [Full Text] [PDF]

				N. Ogier, A. Klein, V. Deckert, A. Athias, G. Bessede, N. Le Guern, L. Lagrost, and C. Desrumaux Cholesterol Accumulation Is Increased in Macrophages of Phospholipid Transfer Protein-Deficient Mice: Normalization by Dietary Alpha-Tocopherol Supplementation Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2407 - 2412. [Abstract] [Full Text] [PDF]

				A. Wehinger, I. Tancevski, W. Schgoer, P. Eller, K. Hochegger, M. Morak, A. Hermetter, A. Ritsch, J. R. Patsch, and B. Foeger Phospholipid Transfer Protein Augments Apoptosis in THP-1-Derived Macrophages Induced by Lipolyzed Hypertriglyceridemic Plasma Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 908 - 915. [Abstract] [Full Text] [PDF]

				R. Vikstedt, D. Ye, J. Metso, R. B. Hildebrand, T. J.C. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck Macrophage Phospholipid Transfer Protein Contributes Significantly to Total Plasma Phospholipid Transfer Activity and Its Deficiency Leads to Diminished Atherosclerotic Lesion Development Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 578 - 586. [Abstract] [Full Text] [PDF]

				R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 190 - 196. [Abstract] [Full Text] [PDF]

				A. Klein, V. Deckert, M. Schneider, F. Dutrillaux, A. Hammann, A. Athias, N. Le Guern, J.-P. Pais de Barros, C. Desrumaux, D. Masson, et al. {alpha}-Tocopherol Modulates Phosphatidylserine Externalization in Erythrocytes: Relevance in Phospholipid Transfer Protein-Deficient Mice Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2160 - 2167. [Abstract] [Full Text] [PDF]

				D. T. Valenta, N. Ogier, G. Bradshaw, A. S. Black, D. J. Bonnet, L. Lagrost, L. K. Curtiss, and C. M. Desrumaux Atheroprotective Potential of Macrophage-Derived Phospholipid Transfer Protein in Low-Density Lipoprotein Receptor-Deficient Mice Is Overcome by Apolipoprotein AI Overexpression Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1572 - 1578. [Abstract] [Full Text] [PDF]

				G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF]

				L. Vogt, G. D. Laverman, A. van Tol, A. K. Groen, G. Navis, and R. P. F. Dullaart Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment Nephrol. Dial. Transplant., January 1, 2006; 21(1): 101 - 106. [Abstract] [Full Text] [PDF]

				X.-C. Jiang, Z. Li, R. Liu, X. P. Yang, M. Pan, L. Lagrost, E. A. Fisher, and K. J. Williams Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants J. Biol. Chem., May 6, 2005; 280(18): 18336 - 18340. [Abstract] [Full Text] [PDF]